Information Provided By: 
Fly News Breaks for February 17, 2017
RARE
Feb 17, 2017 | 11:50 EDT
Wedbush analyst David Nierengarten assumed coverage of Ultragenyx Pharmaceutical with an Outperform rating and lowered his price target for the shares to $88 from $92. With six late stage programs, the analyst is "upbeat" on Ultragenyx's evolution into a mature stand-alone rare disease company with near-term commercial opportunity."
News For RARE From the Last 2 Days
There are no results for your query RARE
